<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04572230</url>
  </required_header>
  <id_info>
    <org_study_id>CDM10001731</org_study_id>
    <nct_id>NCT04572230</nct_id>
  </id_info>
  <brief_title>International Post Market Surveillance Study of Intracranial Aneurysms Treated With an Endovascular Approach</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>IMPACT: International Post Market Product Surveillance Study of IntrACranial Aneurysms Treated With an Endovascular Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Neurovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Neurovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IMPACT is an observational, post market study designed to provide an ongoing safety and&#xD;
      performance evaluation of Stryker Neurovascular devices used for the treatment of&#xD;
      intracranial aneurysms with an endovascular approach.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IMPACT is an international, prospective, observational, multicenter, non-randomized, post&#xD;
      market study designed to provide ongoing safety and performance evaluation on implantable&#xD;
      devices used for the treatment of intracranial aneurysms with an endovascular approach. Data&#xD;
      collection will also include details on adjunctive and ancillary devices used.&#xD;
&#xD;
      In addition to gaining safety and performance data, this study will provide clinical evidence&#xD;
      that may assist physicians in selecting an appropriate device(s) while describing treatment&#xD;
      options used to treat patients with intracranial aneurysms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">October 5, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Performance Measure</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of 100% occlusion of the target aneurysm without significant parent artery stenosis per independant core lab assessent and with no target aneurysm retreatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Stroke-related neurological death or Disabling stroke in the target vessel territory as adjudicated by an independent Clinical Events Committee (CEC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Performance Measures</measure>
    <time_frame>Through 24 months</time_frame>
    <description>Target aneurysm recanalyzation, Parent aretery stenosis ≥ 50%, Target aneurysm retreatment, Target aneurysm occlusion status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Enpoints</measure>
    <time_frame>Through 24 months</time_frame>
    <description>Procedural and device related serious adverse events, Any key neurological event of interest</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endovascular treatment of intracranial aneurysms using a flow-diverting stent</intervention_name>
    <description>The flow diverter brings about a reduction of blood flow to the aneurysm, which progresses over time into forming a stable thrombus within the aneurysm, as well as eventual aneurysm scarring and retraction. The flow diverter also acts as a scaffold for tissue growth across the neck of the aneurysm, which blocks the aneurysm from the artery blood flow.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who have an intracranial aneurysm that the physician intends to treat with a&#xD;
        Stryker Neurovascular device(s).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has an intracranial aneurysm that can be treated with one of the proposed&#xD;
             devices&#xD;
&#xD;
          -  Subject age is ≥ 18 years&#xD;
&#xD;
          -  Subject or subject's legally authorized representative (LAR) has signed written&#xD;
             informed consent&#xD;
&#xD;
          -  Subject is willing to comply with scheduled visits and examinations per institutional&#xD;
             standard of care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is pregnant or plans to become pregnant during her study participation&#xD;
&#xD;
          -  Subject is currently enrolled in or plans to be enrolled in a concurrent drug or&#xD;
             device study&#xD;
&#xD;
          -  Subject has a condition which will not allow him/her to comply with his/her&#xD;
             post-procedure follow up per the institutional standard of care&#xD;
&#xD;
          -  Subject does not meet one of the additional cohort criteria as stated in each&#xD;
             sub-cohort&#xD;
&#xD;
          -  Subject does not meet IFU criteria of the primary device in the sub-cohort protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zsolt Kulcsár, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsspital Zürich, Klinik für Neuroradiologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederic Billaut</last_name>
    <phone>+33 (0) 7 72 55 03 74</phone>
    <email>frederic.billaut@stryker.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uniklinik Salzburg</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Jedlitschka</last_name>
    </contact>
    <investigator>
      <last_name>Monika Killer, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekaterina Saukko</last_name>
    </contact>
    <investigator>
      <last_name>Riitta Rautio, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine Normant</last_name>
    </contact>
    <investigator>
      <last_name>Jean Christophe Gentric, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Charron</last_name>
    </contact>
    <investigator>
      <last_name>Richard Bibi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemelli Hospital</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iacopo Valente, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Alessandro Pedicelli, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Finland</country>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After completion of the 12-month primary endpoint report, and under the guidance of a physician lead publication committee, a multi-center abstract reporting the results will be prepared and may be presented at a major meeting(s). A multi-center publication may also be prepared for publication in a peer reviewed scientific journal.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After completion of the 12-month primary endpoint report</ipd_time_frame>
    <ipd_access_criteria>A final report will be completed describing the results of all pre-specified outcomes, including negative results. The Sponsor will ensure investigators and regulatory authorities will receive the information contained in the final report.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

